Volume 144, Issue 1, Pages (January 2017)

Slides:

Advertisements

Similar presentations

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell

Advertisements

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

ABO-incompatible kidney transplantation Kota Takahashi, Kazuhide Saito Transplantation Reviews Volume 27, Issue 1, Pages 1-8 (January 2013) DOI: /j.trre

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell.

Nicoletta Colombo, Martin Gore

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 148, Issue 1, Pages (January 2018)

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Rajmohan Murali, Rachel N. Grisham, Robert A. Soslow

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Hepatic resection of non-colorectal and non-neuroendocrine liver metastases – Survival benefit for patients with non-gastrointestinal primary cancers.

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 150, Issue 3, Pages (September 2018)

Volume 145, Issue 2, Pages (May 2017)

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 152, Issue 1, Pages (January 2019)

Volume 141, Issue 2, Pages (May 2016)

Volume 135, Issue 1, Pages (October 2014)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 148, Issue 1, Pages (January 2018)

Volume 145, Issue 2, Pages (May 2017)

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 152, Issue 1, (January 2013)

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Volume 152, Issue 1, Pages (January 2019)

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 152, Issue 1, Pages (January 2019)

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? John M. Varlotto,

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Characteristics of primary peritoneal serous carcinoma in a U. S

Volume 152, Issue 1, Pages (January 2019)

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Volume 115, Issue 1, Pages (October 2009)

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage.

Volume 148, Issue 1, (January 2012)

Presentation transcript:

Volume 144, Issue 1, Pages 46-50 (January 2017) Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix M. Frumovitz, M.F. Munsell, J.K. Burzawa, L.A. Byers, P. Ramalingam, J. Brown, R.L. Coleman Gynecologic Oncology Volume 144, Issue 1, Pages 46-50 (January 2017) DOI: 10.1016/j.ygyno.2016.10.040 Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 1 Progression-free survival in patients with small cell cervix cancer treated with topotecan, paclitaxel, and bevacizumab (TPB) or only with non-TPB regimens as primary therapy for first recurrence. Gynecologic Oncology 2017 144, 46-50DOI: (10.1016/j.ygyno.2016.10.040) Copyright © 2016 Elsevier Inc. Terms and Conditions

Fig. 2 Overall survival in patients with small cell cervix cancer treated with topotecan, paclitaxel, and bevacizumab (TPB) or only with non-TPB regimens as primary therapy for first recurrence. Gynecologic Oncology 2017 144, 46-50DOI: (10.1016/j.ygyno.2016.10.040) Copyright © 2016 Elsevier Inc. Terms and Conditions